These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35601587)

  • 21. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
    Langley P
    F1000Res; 2022; 11():993. PubMed ID: 36226039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology Assessment.
    Langley PC
    Innov Pharm; 2018; 9(3):1-5. PubMed ID: 34007719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 26. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.
    Langley PC
    Innov Pharm; 2022; 13(3):. PubMed ID: 36627905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 31. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
    Bloudek LM; Nguyen V; Grueger J; Sullivan SD
    Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abandoning Eugenics and the QALY.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 35. A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.